1. Introduction {#sec1}
===============

Meningiomas are the second most common primary intracranial tumor. Meningiomas present clinically by causing focal or generalized seizure disorders, focal neurological deficits or neuropsychological decline \[[@B1]\]. A large number of molecular and genetic pathways that are altered in brain tumor cells have been identified. Among them, a possible role for the eicosanoid cascade has been suggested in meningiomas \[[@B2]\]. Phospholipase A~2~ (PLA~2~) is the key enzyme involved in eicosanoid generation \[[@B3]--[@B5]\]. PLA~2~ catalyzes the hydrolysis of the *sn*-2 position of membrane glycerophospholipids to liberate the eicosanoid precursor arachidonic acid (AA) \[[@B3]--[@B5]\]. Four distinct families have been documented: low molecular weight secreted forms of PLA~2~ (sPLA~2~), Ca^2+^-dependent high molecular weight PLA~2~ (cPLA~2~), Ca^2+^-independent high molecular weight PLA~2~ (iPLA~2~); and the platelet-activating factor acetylhydrolase (PAF-AH). The sPLA~2~ family is implicated in several biological processes such as inflammation and host defense \[[@B3], [@B4]\]. Nine isoenzymes have been identified in human: PLA~2~-IB, PLA~2~-IIA, PLA~2~-IID, PLA~2~-IIE PLA~2~-IIF, PLA~2~-III, PLA~2~-V, PLA~2~-X, PLA~2~-XIIA, and PLA~2~-XIIB. In addition to their function in digestion of dietary phospholipids, host defense against bacteria and AA release from cellular phospholipids for eicosanoid synthesis, two classes of receptors (M and N) and several extracellular binding proteins have been identified indicating that sPLA~2~ might signal through receptor activation \[[@B3]--[@B5]\]. In human the cPLA~2~ family consists of four members, PLA~2~-IVA, PLA~2~-IVB, PLA~2~-IVC, and PLA~2~-IVD; PLA~2~-IVA being the central regulator of stimulus-coupled cellular AA release \[[@B3]--[@B5]\]. In human the iPLA~2~ group consists of seven members, iPLA~2~ (PLA~2~-VIA-1) currently being the best known member and playing major role in phospholipids remodeling and cancer \[[@B3], [@B5]\]. Beside its important place for eicosanoid generation, PLA~2~ is also the key enzyme for the generation of the pro-inflammatory lipid mediator PAF recently documented in human meningioma \[[@B6]\]. PAF-AH activity which hydrolysis PAF into the inactive PAF precursor, lyso-PAF is detected in meningioma \[[@B6]\]. However no results reported whether this enzymatic activity originated from PLA~2~-VIIA and/or PLA~2~-VIIB, the plasma PAF-AH and the intracellular PAF-AH forms, respectively. Currently the contribution of PLA~2~ in meningiomas is poorly documented despite the fact that PLA~2~ inhibition decreased the growth of cultured meningioma cells \[[@B7]\]. In view of the potentially important oncogenic action of the various PLA~2~ species, we investigated, at the mRNA levels, which of them were expressed in intracranial human meningiomas.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

The procedure of the present study followed the rules edited by the French National Ethics. Ethics approval was obtained from the ethics committee of our hospital (CHU Dupuytren, Limoges, France). Twenty six patients who underwent surgery for intracranial meningiomas (from 1998 to 2004) were investigated. Tumors were from the Service d\'Anatomie Pathologique of the CHU Dupuytren (France). After undergoing the routine hospital analysis, the excess of sample was kept at −80°C until use and this in accordance with the regulations in force in France. No written or oral consent was obtained because it is a study of samples already collected and referred to research prior the French bioethical low (2004). Thus, ethics committee explicitly approved the waiver of consent. Normal meninges were not available in our institution in light of our ethic committee law. The low amounts (10--15 mg) of available tumors only permitted investigations at the mRNA level. Tumors were classified according to the WHO criteria \[[@B8]\]. There were 16 grade I meningiomas including 8 transitional (2 man, 6 women, mean age 60 years), 3 meningothelial (1 man, 2 women, mean age 60 years), and 5 fibrous (5 women, mean age 59 years). Height tumors were grade II meningiomas: 7 atypical (6 men, 1 woman, mean age 58 years) and 1 chordoid meningiomas (1 man, 54 years). Two tumors were classified as anaplastic grade III meningiomas (2 men, mean age 54 years). Necrosis was assessed using morphological criteria defined by the WHO classification of meningiomas: "foci of spontaneous or geographic necrosis". The chronic inflammatory infiltrate was mainly lymphoplasmocytic.

2.2. RNA Extraction {#sec2.2}
-------------------

Total RNA was extracted using the "RNeasy Lipid Tissue mini kit" (Qiagen, Courtaboeuf, France) from 10--15 mg of tumor tissue. Before RNA extraction, tumor fragments were incubated with 14mm ceramic beads "Lysing matrix D" (Bertin Technologies, Montigny-Le-Bretonneux, France) in 1 mL QIAzol lysis reagent and homogenized at 5500 rpm during 2-fold 40 sec in the automated mixer Precellys (Bertin Technologies). Then homogenized samples were used for RNA purification according to the manufacturer\'s protocol. A DNase I digestion step was included for each extraction to avoid RNA contamination by genomic DNA. RNA integrity was checked by capillary electrophoresis on the Bioanalyzer 2100 (Agilent Technologies, Massy, France). Only RNA with an RNA Integrity Number (R.I.N) higher than 5.5 was used for reverse transcription. Total RNA concentration was determined by measuring absorbance at 260 nm with a spectrophotometre NanoDrop ND-1000 (Labtech, Paris, France).

2.3. Reverse Transcription {#sec2.3}
--------------------------

Total RNA was reverse transcribed in single strand cDNA using random hexamers and as described in the protocol of the "SuperScript III First-Strand Synthesis System for RT-PCR" (Invitrogen, Cergy-Pontoise, France). Briefly, 1 *μ*g total RNA was incubated with 200 U M-MLV reverse transcriptase in the presence of 0.5 mM dNTPs, 50 ng random hexamers, 5 mM MgCl~2~, 10 mM dithiotreitol, and 40 U RNase inhibitor, in a final volume of 20 *μ*L 1X RT buffer. Reverse transcription was performed as follows in a thermocycler Gold 9700 (Applied Biosystem): denaturation during 5 min at 65°C and chilling 1 min on ice, hybridization during 10 min at 25°C followed by cDNA synthesis during 50 min at 50°C; enzyme was inactivated by a 5 min incubation at 85°C and chilling on ice; finally the destruction of the RNA portion of the RNA:cDNA hybrids was performed by 2 U RNase H during 20 min at 37°C. Reactions were frozen at −20°C until quantitative real-time PCR realisation.

2.4. Real-Time PCR Analysis {#sec2.4}
---------------------------

PLA~2~-IB, PLA~2~-IIA, PLA~2~-IID, PLA~2~-IIE, PLA~2~-IIF, PLA~2~-III, PLA~2~-IVA, PLA~2~-IVB, PLA~2~-IVC, PLA~2~-IVD, PLA~2~-V, PLA~2~-VI, PLA~2~-X, PLA~2~-XIIA, PLA~2~-XIIB, PLA~2~-VIIA (plasma PAF-AH), PLA~2~-VIIB (intracellular PAF-AH), and PLA~2~R transcripts were analyzed using real-time polymerase chain reaction (PCR). PCR was performed in duplicate by using TaqMan assay reagents (Applied Biosystems, Foster City, CA) \[[@B9], [@B10]\]. Product references were the following: PLA~2~-IB: Hs00386701-m1; PLA~2~-IIA: Hs00179898-m1; PLA~2~-IID: Hs00173860-m1 PLA~2~-IIE: Hs00173897-m1; PLA~2~-IIF: Hs00224482-m1; PLA~2~-III: Hs00210447-m1; PLA~2~-IVA: Hs00233352-m1; PLA~2~-IVB: Hs00979952-m1; PLA~2~-IVC: Hs00234345-m1; PLA~2~-IVD: Hs00603557-m1; PLA~2~-V: Hs00173472-m1; PLA~2~-VI: Hs001/85926-m1; PLA~2~-X: Hs00358567-m1; PLA~2~-XIIA: Hs00830106-s1; PLA~2~-XIIB: Hs00261432-m1; PLA~2~-VIIA: Hs00968593-m1; PLA~2~-VIIB: Hs01042135-m1; PLA~2~R: Hs00234853-m1. Real-time PCR were performed following the recommendations of the manufacturer in a final volume of 20 *μ*l with 10 *μ*l of 2X Universal PCR Master Mix, 20 ng of cDNA in a volume of 9 *μ*l (the amount of cDNA is an equivalent based on the initial amount of RNA used for the RT reaction and 1 *μ*l of a 20X TaqMan gene expression specific probe. PCR parameters were the following: 95°C for 10 min and forty cycles of 95°C/15 sec and 60°C/60 sec. Amplification products were analyzed on an ABI Prism 7000 system (Applied Biosystems) \[[@B9], [@B10]\]. Gene expression levels were normalized to 18S RNA (product reference: Hs99999901-s1) according to the manufacturer\'s recommendation. Amounts of various transcripts were compared to sample with the lowest level of transcripts (a patient who was arbitrary quoted 1). The relative quantification of gene expression was performed using the comparative *C* ~*T*~ method (∆∆*C* ~*T*~) ([Figure 1(a)](#fig1){ref-type="fig"}). Experiments were made in duplicate. Mean *C* ~*T*~ values were used in the ∆∆*C* ~*T*~ calculation by using the "relative quantitation calculation and analysis software for Applied Biosystems real-time PCR systems". NonRT controls (only with RNA) and blank RT controls (RT without RNA) were run to make sure the amplifications were specifics.

2.5. Data Analysis {#sec2.5}
------------------

Significance was assessed by using the Kruskal-Wallis test followed by a Mann-Whitney *U*-test.

3. Results and Discussion {#sec3}
=========================

In a first set of experiments we investigated if mRNAs derived from the five intracellular PLA~2~ genes (four cPLA~2~ and iPLA~2~) were detected in meningiomas. As shown in [Figure 1(b)](#fig1){ref-type="fig"}, mRNAs derived from four of these five cloned PLA~2~ genes are detected. Mean *C* ~*T*~ values are reported in [Table 1](#tab1){ref-type="table"}. PLA~2~-IVD transcripts were not present at detectable levels. In contrast, PLA~2~-IVA, PLA~2~-IVB, PLA~2~-IVC, and PLA~2~-VI were detected in 96% (25/26), 100% (26/26), 92% (24/26), and 100% (26/26) of tumors, respectively ([Figure 2](#fig2){ref-type="fig"}). These results confirm a previous study highlighting PLA~2~ activity in 100% of human meningiomas \[[@B6]\]. No difference (*P* \> .05, Mann Whitney *U*-test) was found for PLA~2~ transcript amounts in relation to the tumor grade ([Figure 1](#fig1){ref-type="fig"}), nor the subtype of meningiomas, the presence of inflammatory infiltrated cells, of an associated edema, mitosis, brain invasion, vascularisation or necrosis (data not shown). The analysis of twenty six patients indicated the following rank of magnitude in human meningiomas: PLA~2~-VI = PLA~2~-IVB \> PLA~2~-IVA \> PLA~2~-IVC ([Table 1](#tab1){ref-type="table"}). PLA~2~-IVB and PLA~2~-IVC had little specificity for the *sn*-2 fatty acid as compared with PLA~2~-IVA which preferentially hydrolyses phospholipids containing AA at the *sn*-2 position \[[@B3]--[@B5]\]. PLA~2~-VI was originally reported to mediate phospholipid remodeling and, thus, to act as a housekeeping protein without significant role in cell growth \[[@B3], [@B4]\]. However several recent studies have demonstrated that PLA~2~-VI exhibited roles in cell regulation, growth, and death. Especially, one mechanism by which PLA~2~-VI mediates cell growth involves regulation of AA release, p53, and MAPK activation \[[@B11]\]. Of interest, involvements of p53 and MAPK kinase have been recently reported in the pathology of human meningiomas \[[@B12], [@B13]\]. A role for PLA~2~-VI may, thus, be suggested in meningioma tumor growth. Together, these observations might suggest PLA~2~-VI as a novel and interesting target for drug development for meningioma therapy. However, given the ubiquitous expression of PLA~2~-VI and its role in glycerophospholipid metabolism, drug strategies targeting PLA~2~-VI must exhibit selectivity to avoid undesired side effects.

In a second set of experiments we investigated if mRNAs derived from the nine sPLA~2~ genes (i.e., PLA~2~-IB, PLA~2~-IIA, PLA~2~-IID, PLA~2~-IIE, PLA~2~-IIF, PLA~2~-III, PLA~2~-V, PLA~2~-X, PLA~2~-XIIA, and PLA~2~-XIIB) were detected in human meningiomas. PLA~2~-IIE, PLA~2~-IIF, and PLA~2~-XIIB transcripts were not present at detectable levels in tumors while PLA~2~-IID and PLA~2~-X transcripts were detected in only a few number (4/26, 15%) of them. In contrast, PLA~2~-IB, PLA~2~-IIA, PLA~2~-III, PLA~2~-V and PLA~2~-XIIA were detected in 88% (23/26), 88% (23/26), 77% (20/26), 65% (17/26), and 96% (25/26) of tumors, respectively ([Figure 3](#fig3){ref-type="fig"}). Mean C~T~ values are reported in [Table 1](#tab1){ref-type="table"}. Results indicated the following rank of magnitude for sPLA~2~ transcripts in meningiomas: PLA~2~-XIIA \> PLA~2~-IIA \> PLA~2~-IB = PLA~2~-V = PLA~2~-III = PLA~2~-IID \> PLA~2~-X. No difference (*P* \> .05, Mann Whitney *U*-test) was found for sPLA~2~ transcript amounts in relation to the tumor grade ([Figure 3](#fig3){ref-type="fig"}), nor the subtype of meningiomas, the presence of inflammatory infiltrated cells, of an associated edema, mitosis, brain invasion, vascularisation or necrosis (data not shown). PLA~2~-XIIA, PLA~2~-IIA, and PLA~2~-IB might be implicated in meningioma growth. The physiologic roles of PLA~2~-XIIA remain an open question. Whether PLA~2~-XIIA exhibits a weak AA catalytic activity \[[@B14]\], a potential role for this enzyme is suggested in membrane fusion or cell division \[[@B15]\]. PLA~2~-XIIA was reported to inhibit bone morphogenetic protein (BMP) through the loss of activated Smad1/4 complexes \[[@B16]\]; a result of importance since BMP inhibits the tumorigenic potential of human glioblastomas by triggering the Smad signaling cascade \[[@B17]\]. PLA~2~-IB expression is mainly neuronal in human brain \[[@B18]\]. Apart from its lipolytic and pro-inflammatory activities, PLA~2~-IB acts as receptor ligand to induce cell signaling and subsequent activation of cPLA~2~, thus indirectly contributing to AA production \[[@B19]\]. However the role of PLA~2~-IB as a ligand for the PLA~2~R is still controversial. PLA~2~-IIA elicits a mitogenic response and activates AA metabolism in astrocytoma cells \[[@B20]\], is critical for neuronal death via reactive oxygen species \[[@B21]\] and plays a role in cellular senescence \[[@B22]\]. Finally, studies have suggested the role of PLA~2~-IIA, PLA~2~-III, and PLA~2~-V as potential prognostic markers in colorectal adenocarcinomas and prostate cancer \[[@B23], [@B24]\]. The data reported in [Figure 3](#fig3){ref-type="fig"}suggest that levels of PLA~2~-IIA, PLA~2~-III, and PLA~2~-V transcripts greatly varied between patients (see the Log scale). Would it be possible that their levels were related to patient outcomes in meningioma tumors? Clearly investigation of a larger number of patients would be of interest to test this hypothesis.

In a third set of experiments we investigated PAF-AH enzymes that constitute another PLA~2~ subfamily. As shown in [Figure 4](#fig4){ref-type="fig"}(upper panel), PLA~2~-VIIA (the plasma PAF-AH form) and PLA~2~-VIIB (the intracellular PAF-AH form) were present in 100% (23/23) and 95% (22/23) meningioma tumors. Mean C~T~ values are reported in [Table 1](#tab1){ref-type="table"}. No difference (*P* \> .05, Mann Whitney *U*-test) was found for PAF-AH transcript amounts in relation to the tumor grade ([Figure 4(a)](#fig4){ref-type="fig"}), nor to other clinical data (data not shown). The present results confirm a previous study reporting PAF-AH enzymatic activity in meningioma homogenates \[[@B6]\]. The PAF-AH family exhibits unique substrate specificity toward PAF and oxidized phospholipids. Degradation of these bioactive phospholipids by PAF-AH may lead to the termination of inflammatory reaction. Its presence in human meningioma is consistent with the presence of PAF in meningioma tumors \[[@B6], [@B25]\].

Finally in a fourth set of experiments we focused our attention on PLA~2~R transcripts in human meningioma. As shown in [Figure 4](#fig4){ref-type="fig"}(lower panel), PLA~2~R transcripts were detected in 100% (23/23) meningioma tumors but without significant link with the tumor grade. The PLA~2~R can act as a ligand for several sPLA~2~ thus mediating a variety of biological responses (such as cell proliferation, cell migration, hormone release, lipid mediator production and cytokine production). In turn, PLA~2~R can also play a negative role in sPLA~2~ functions by downregulating their exaggerated reactions as PLA~2~R is involved in the degradation/internalization of sPLA~2~ \[[@B26]\]. Particularly, PLA~2~R deficient mice exhibit resistance to endotoxic shock \[[@B27]\] and knockdown of the PLA~2~R prevents the onset of replicative senescence and diminishes stress-induced senescence \[[@B28]\]. Finally PLA~2~R was found to be upregulated in dermatofibrosarcoma \[[@B29]\].

In conclusion, numerous genes encoding multiples forms of cPLA~2~, sPLA~2~, and PAF-AH are expressed (at the mRNA level) in human meningiomas where they might act on tumor growth not only by acting on phospholipid remodeling but also by altering the local eicosanoid and/or cytokine networks. It is of evidence that immunhistochemistry would be of importance to confirm the relative expression of the different PLA~2~ forms in human meningioma tumors. The discovery of specific receptors that bind sPLA~2~ strongly indicate that these enzymes can exert various biological responses via binding to a receptor, in addition to their enzymatic activity. Of interest meningioma tumors expressed PLA~2~R transcripts. Further studies are clearly needed to elucidate the contributions of sPLA~2~, cPLA~2~, iPLA~2~, and PAF-AH in meningioma and to determine their possible relevance in the targeting of new therapeutic interventions.
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![Q-PCR analysis of PLA~2~ transcripts in human meningioma tumors. (a) Representative tracing of 18S and PLA~2~-IVA of tumors from 2 different patients (duplicate samples). (b) Detection (in duplicate) of 18S, PLA~2~-IVA, PLA~2~-IVB, PLA~2~-IVC, PLA~2~-IVD, and PLA~2~-VI in a meningioma tumor.](MI2009-689430.001){#fig1}

![Cytosolic PLA~2~ transcripts in human meningiomas. Sixteen-grade I and eleven-grade II+III meningiomas were investigated. Gene expression levels were normalized to 18S RNA. Amounts of transcripts were compared to sample with the lowest level of transcripts (a patient who was arbitrary quoted 1). (∘) indicates patients with no detectable transcripts. No significant differences were documented between groups.](MI2009-689430.002){#fig2}

![Secreted PLA~2~ transcripts in human meningiomas. Same legend as in [Figure 2](#fig2){ref-type="fig"}. (∘) indicates patients with no detectable transcripts. No significant differences were documented between groups.](MI2009-689430.003){#fig3}

![PAF-AH and PLA~2~R transcripts in human meningiomas. Upper panel: plasma PAF-AH (PLA~2~-VIIA) and intracellular PAF-AH (PLA~2~-VIIB) in meningioma tumors. Fifteen-grade I and nine-grade II+III meningiomas were investigated. (∘) indicates patients with no detectable transcript. No significant differences were documented between groups. Lower panel: PLA~2~R transcripts in fifteen-grade I and nine-grade II+III meningiomas.](MI2009-689430.004){#fig4}

###### 

*C* ~*T*~ values obtained during real-time PCR analysis.

                Mean ± SEM *C* ~*T*~ (made on detectable samples)   Number of samples with a *C* ~*T*~ \> 40 (nondetectable samples)
  ------------- --------------------------------------------------- ------------------------------------------------------------------
  18S           12.27 ± 0.18                                        0
  PLA~2~-IB     35.35 ± 0.29                                        3
  PLA~2~-IIA    33.69 ± 0.74                                        3
  PLA~2~-IID    34.91 ± 0.81                                        22
  PLA~2~-IIE    nd                                                  26
  PLA~2~-IIF    nd                                                  26
  PLA~2~-III    35.28 ± 0.50                                        6
  PLA~2~-IVA    32.3 ± 0.27                                         1
  PLA~2~-IVB    30.57 ± 0.33                                        0
  PLA~2~-IVC    33.9 ± 0.35                                         2
  PLA~2~-IVD    nd                                                  26
  PLA~2~-V      35.81 ± 0.61                                        9
  PLA~2~-VI     30.78 ± 0.30                                        0
  PLA~2~-VIIA   33.19 ± 0.48                                        0
  PLA~2~-VIIB   30.25 ± 1.21                                        1
  PLA~2~-X      37.93 ± 0.26                                        22
  PLA~2~-XIIA   32.86 ± 0.33                                        1
  PLA~2~-XIIB   nd                                                  26

Results are reported as mean ± SEM of 26 experiments excepted for PLA~2~-VIIA and PLA~2~-VIIB were 23 samples were analysed. nd: not detectable *C* ~*T*~.
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